Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

ACUTE

all patients

Back
1st line – 

intensive care management

Patients with ALF with grade 2 or higher hepatic encephalopathy should be admitted to an intensive care unit (ICU).[4]​ The natural history of ALF may be characterised by a rapid deterioration in neurological status, high risk of complications including sepsis and cerebral oedema, haemodynamic instability, and renal failure. Intensive care unit monitoring is critical in providing optimal care of the patient and to prevent and treat known complications of ALF.

Efforts should be made to minimise elevations of intracranial pressure. The head of the patient's bed should be raised to approximately 30 degrees and surrounding stimuli reduced to a minimum.[51] Once advanced encephalopathy develops (grades 3 or 4), tracheal intubation should be performed for airway protection.[4]​ Propofol and fentanyl are preferred agents for analgesia and sedation due to their short half-lives. Intravenous fluids should be administered with caution to prevent depletion or volume overload; central venous pressure and pulmonary arterial monitoring as well as renal replacement therapy should be considered early to ensure optimal fluid management, particularly if there is evidence of renal or circulatory dysfunction.[8][100]


Tracheal intubation animated demonstration
Tracheal intubation animated demonstration

How to insert a tracheal tube in an adult using a laryngoscope.



Bag-valve-mask ventilation animated demonstration
Bag-valve-mask ventilation animated demonstration

How to use bag-valve-mask apparatus to deliver ventilatory support to adults. Video demonstrates the two-person technique.


Enteral nutrition is generally a concern in the setting of encephalopathy, in which the patient is unable to obtain adequate nutrition due to an altered mental status. Therefore, enteral nutritional support with calorie-dense feeds should also be initiated early during the hospital course.

Prophylactic antimicrobial therapy does not appear to influence outcome and is not recommended.[4][104] However, empirical antimicrobials are recommended if a patient develops positive surveillance cultures, refractory hypotension, progression to grade 3 to 4 hepatic encephalopathy, evidence of Systemic Inflammatory Response Syndrome; and in all patients who are listed for liver transplantation.[100]

Proton-pump inhibitors or H2 antagonists should be administered as prophylaxis of gastrointestinal bleeding secondary to coagulopathy.[8]

Back
Plus – 

liver transplantation assessment

Treatment recommended for ALL patients in selected patient group

Criteria for United Network for Organ Sharing (UNOS) Status 1A designation include: age >18 years, life expectancy without a liver transplant of <7 days, onset of encephalopathy within 8 weeks of the first symptoms of liver disease, absence of pre-existing liver disease, admission to an intensive care unit, and 1 of the following: ventilator dependence, requirement of renal replacement therapy, or INR >2.0. UNOS status 1A patients are listed with top priority for liver allocation. Wilson's disease may also be given Status 1A priority.

Contraindications to liver transplantation include severe cardiac or pulmonary disease, AIDS, extrahepatic malignancy, metastatic hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uncontrolled sepsis, irreversible neurological complications (e.g., brain death, intracerebral haemorrhage, intractable sustained raised intracranial pressure), ongoing alcohol or illicit substance misuse, and lack of an adequate social support system.[48]


Central venous catheter insertion animated demonstration
Central venous catheter insertion animated demonstration

Ultrasound-guided insertion of a non-tunnelled central venous catheter (CVC) into the right internal jugular vein using the Seldinger insertion technique.


Back
Plus – 

neurological status monitoring for advanced encephalopathy

Treatment recommended for ALL patients in selected patient group

Neurological status should be monitored carefully and regularly for the development of advanced encephalopathy (grade 3 to 4), which is associated with a greater risk of cerebral oedema and intracranial hypertension.

Head of the patient's bed should be raised to 30 degrees and surrounding stimuli reduced. Tracheal intubation and sedation with intravenous propofol or fentanyl should be performed once advanced encephalopathy develops. Central venous pressure monitoring, pulmonary arterial monitoring, and renal replacement therapy should be considered early.


Tracheal intubation animated demonstration
Tracheal intubation animated demonstration

How to insert a tracheal tube in an adult using a laryngoscope.



Bag-valve-mask ventilation animated demonstration
Bag-valve-mask ventilation animated demonstration

How to use bag-valve-mask apparatus to deliver ventilatory support to adults. Video demonstrates the two-person technique.


Back
Plus – 

monitoring of blood glucose, electrolytes, and cultures

Treatment recommended for ALL patients in selected patient group

Blood glucose levels should be monitored every 1 to 2 hours by finger stick to assess for hypoglycaemia. Hypoglycaemia should be corrected with intravenous glucose infusion, with a glycaemic target of 140 mg/dL.[51]

Serum electrolytes, including sodium, phosphate, potassium, and magnesium, should be monitored at least twice daily and corrected aggressively.

In patients with advanced encephalopathy (grade 3 or 4), surveillance cultures from blood, urine, and sputum should be obtained periodically given the high risk of bacterial and fungal infection; however, no clear impact of prophylactic antimicrobials has been shown.

Other routine laboratory studies such as coagulation activity, blood cell counts, and liver enzymes should also be monitored closely at regular intervals.

Back
Plus – 

acetylcysteine

Treatment recommended for ALL patients in selected patient group

Acetylcysteine therapy should be given in all cases of paracetamol overdose regardless of the dose or timing of paracetamol ingestion. See Paracetamol overdose.

Acetylcysteine therapy is also recommended for patients with mild to moderate hepatic encephalopathy, even when paracetamol has not been ingested.[105] Based on available evidence, the American College of Gastroenterology recommends using intravenous acetylcysteine in patients with non-paracetamol ALF.[4]​ In particular, a short course of intravenous acetylcysteine may be of benefit for hospitalised adult patients with ALF secondary to a drug-induced liver injury, but it is not recommended in children.[30]

Oral acetylcysteine may be given in patients with up to grade 1 hepatic encephalopathy. Intravenous acetylcysteine is preferred for higher grades of hepatic encephalopathy or if the patient is intolerant of oral intake, has ileus or is pregnant, and should be accompanied by telemetry monitoring.[4][30]

Acetylcysteine therapy should continue until end points such as improvement of hepatic function by clinical and laboratory parameters have been achieved.[23][30][100]

Primary options

acetylcysteine: consult specialist for guidance on dose

Back
Consider – 

activated charcoal

Additional treatment recommended for SOME patients in selected patient group

In patients with paracetamol overdose in whom ingestion is known to have occurred within 4 hours, a single-dose of activated charcoal can be given.[4]

Primary options

activated charcoal: 25-100 g orally as a single dose

Back
Plus – 

aciclovir

Treatment recommended for ALL patients in selected patient group

May have positive impact on clinical outcome.[8]

Primary options

aciclovir: 10 mg/kg intravenously every 8 hours

Back
Plus – 

expedient delivery of the fetus

Treatment recommended for ALL patients in selected patient group

Prompt delivery of the fetus may have a positive impact on clinical outcome.[8]​ In addition to this approach, supportive care and multidisciplinary management are recommended.[4]​ If patient’s condition fails to improve after delivery, liver transplantation may be considered.

Back
Plus – 

intravenous fluids + gastric lavage + activated charcoal

Treatment recommended for ALL patients in selected patient group

Contact the poison control centre for guidance. Continued supportive management includes intravenous fluids.[4]

Primary options

activated charcoal: 25-100 g as a single dose, repeat every 4-6 hours if required

Back
Plus – 

benzylpenicillin

Treatment recommended for ALL patients in selected patient group

Amatoxins inhibit hepatocyte RNA polymerase II, leading to cell necrosis. Beta-lactam antibiotics are thought to be hepatoprotective in the setting of amanita toxicity. This has been reported through in vitro experiments, studies with animal models, and in the clinical setting following Amanita phalloides ingestion by humans, in which intravenous penicillin has been associated with clinical recovery and improved survival. The exact mechanism has not been well defined; however, it may be associated with blocking of amatoxin uptake by hepatocytes.[4][30][100][123][124]

Primary options

benzylpenicillin sodium: 2.4 to 4.8 g/day intravenously in 4 divided doses

Back
Plus – 

acetylcysteine

Treatment recommended for ALL patients in selected patient group

Oral acetylcysteine may be given in patients with up to grade 1 hepatic encephalopathy. Intravenous acetylcysteine is preferred for higher grades of hepatic encephalopathy, or if the patient is intolerant to oral intake, has ileus or is pregnant; telemetry monitoring is recommended for intravenous dosing.

Acetylcysteine therapy should continue until end points such as improvement of hepatic function by clinical and laboratory parameters have been achieved.[23][30][100]

Primary options

acetylcysteine: consult specialist for guidance on dose

Back
Plus – 

methylprednisolone

Treatment recommended for ALL patients in selected patient group

In acute presentations of autoimmune hepatitis resulting in ALF, corticosteroids may have some benefit; however, data are conflicting.[7][111] In the absence of clear prospective data, this potential benefit is uncertain.

Primary options

methylprednisolone sodium succinate: 60 mg intravenously once daily

Back
Plus – 

oral nucleoside or nucleotide analogue

Treatment recommended for ALL patients in selected patient group

Studies are limited, although antiviral therapy may have benefit and should be considered. Entecavir or tenofovir are the preferred agents.

Primary options

entecavir: 0.5 mg orally/nasogastrically once daily

OR

tenofovir disoproxil: 300 mg orally/nasogastrically once daily

Back
Plus – 

anticoagulation

Treatment recommended for ALL patients in selected patient group

Patients should be assessed for an underlying hypercoagulable disorder or myeloproliferative disease. Anticoagulation therapy (e.g., low-molecular-weight heparin) should be initiated in all patients.[4]

Budd-Chiari syndrome is defined by hepatic outflow obstruction secondary to thrombosis at the level of the hepatic veins or suprahepatic inferior vena cava in the absence of cardiac disease. A key factor in the pathogenesis of Budd-Chiari syndrome is the presence of an underlying prothrombotic condition, which can be identified in the majority of cases. Thus, all patients presenting with Budd-Chiari syndrome should be considered for immediate anticoagulation therapy.

Back
Consider – 

transjugular intrahepatic portosystemic shunt (TIPS)

Additional treatment recommended for SOME patients in selected patient group

Hepatic vein angioplasty with stent or transjugular intrahepatic portosystemic shunt (TIPS) placement may be considered in patients not responding to anticoagulation.[4]​ However, some may ultimately require liver transplantation.

Back
Consider – 

measures to decrease serum copper

Additional treatment recommended for SOME patients in selected patient group

Acute Wilson's disease with ALF is associated with high mortality despite measures to decrease serum copper levels, including plasmapheresis, continuous veno-venous haemofiltration, albumin dialysis, or plasma exchange. Chelation therapy for Wilson's disease in the setting of ALF is generally ineffective, may be associated with hypersensitivity, and is not recommended.

Back
Plus – 

liver transplant

Treatment recommended for ALL patients in selected patient group

Wilson's disease should be suspected in any patient presenting with ALF with non-immune haemolytic anaemia including acute intravascular haemolysis. These patients should be urgently evaluated for liver transplantation.[43]

Patients with ALF who fulfil listing criteria, according to the United Network for Organ Sharing (UNOS), may be assigned category Status 1A and listed with top priority for liver allocation. Criteria for UNOS Status 1A designation include: age >18 years, life expectancy without a liver transplant of <7 days, onset of encephalopathy within 8 weeks of the first symptoms of liver disease, absence of pre-existing liver disease, admission to an intensive care unit, and 1 of the following: ventilator dependence, requirement of renal replacement therapy, or INR >2.0. Patients with acute fulminant Wilson's disease may also be given Status 1A priority.

Contraindications to liver transplantation for ALF include severe cardiac or pulmonary disease, AIDS, extrahepatic malignancy, metastatic hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uncontrolled sepsis, irreversible neurological complications (e.g., brain death, intracerebral haemorrhage, intractable sustained raised intracranial pressure), ongoing alcohol or illicit substance misuse, and lack of an adequate social support system.[48]


Central venous catheter insertion animated demonstration
Central venous catheter insertion animated demonstration

Ultrasound-guided insertion of a non-tunnelled central venous catheter (CVC) into the right internal jugular vein using the Seldinger insertion technique.


back arrow

Choose a patient group to see our recommendations

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer

Use of this content is subject to our disclaimer